Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Danuglipron iconDanuglipronSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Danuglipron

Beginner tier: 10 mg, 2x daily · clinical trials

Weight LossResearch
~6-8 hours half-life·Oral

Also known as: PF-06882961

Pfizer spent years building an oral GLP-1 pill that didn't need injections, absorption enhancers, or fasting windows. Danuglipron (PF-06882961) is a non-peptide small molecule that activates the GLP-1 receptor from an allosteric binding site. Phase 2b data in 626 adults with obesity showed placebo-adjusted weight loss of 5 to 13 percent at 32 weeks. The problem was tolerability. Nausea hit up to 73 percent of participants at the highest dose arms in the obesity trial. Vomiting reached 47 percent at the highest dose arms in the obesity trial. More than half dropped out. Then a single case of drug-induced liver injury prompted Pfizer to shut down the entire program in April 2025.

What Is Danuglipron?

Danuglipron (PF-06882961, CAS 2230198-02-2) is a small molecule GLP-1 receptor agonist, not a peptide. Pfizer developed it as an oral alternative to injectable GLP-1 drugs, and the Phase 2b obesity trial showed 8 to 13 percent placebo-adjusted weight loss. Pfizer discontinued all development in April 2025.

The molecule binds an allosteric site on the GLP-1 receptor, separate from the orthosteric pocket where semaglutide and native GLP-1 attach. That distinction matters because it means the molecule is orally bioavailable without help. Oral semaglutide (Rybelsus) requires a permeation enhancer and an empty stomach. Danuglipron works with or without food.

The Phase 2b obesity trial (626 participants, 26 to 32 weeks)[1] confirmed the weight loss numbers. At the highest doses, completers lost 5 to 13 percent more than placebo at 32 weeks. In the 16-week type 2 diabetes trial [4], HbA1c fell by up to 1.16 percent versus placebo, fasting glucose by up to 33 mg/dL.

But 61 percent of obesity trial participants never finished. Thirty-eight percent quit because of side effects, mostly nausea and vomiting. That 5 to 13 percent weight loss figure reflects survivorship bias; the people who tolerated the drug did well. The short half-life of roughly 6 to 8 hours forced twice-daily dosing, and Pfizer was developing an extended-release version when a single participant in a dose-optimization study showed raised liver enzymes consistent with drug-induced liver injury. That participant recovered after stopping the drug, and overall liver enzyme rates across 1,400 participants looked similar to approved GLP-1 drugs. Pfizer discontinued all development in April 2025 anyway. The drug is not available commercially, through compounding pharmacies, or for any clinical use.

How Danuglipron Works

Danuglipron activates the GLP-1 receptor without touching the same binding pocket as semaglutide or native GLP-1. It is a non-peptide allosteric agonist, meaning it locks onto a different part of the receptor surface and stabilizes an active conformation from there.

Once the receptor is active, the downstream signaling is familiar. Gs-protein coupling raises intracellular cAMP in pancreatic beta cells. Insulin secretion increases, but only when glucose is present. Glucagon release from alpha cells drops. Gastric emptying slows. Appetite suppression kicks in through hypothalamic and brainstem GLP-1 receptors.

The molecular weight sits around 556 g/mol. That's small enough to survive proteolytic enzymes in the GI tract. Pharmacokinetic studies confirmed similar plasma exposure in fed and fasted states; food doesn't change absorption (Phase 1 MAD study)[3]. Primary metabolism runs through hepatic pathways.

The short half-life, approximately 6 to 8 hours, is the defining pharmacokinetic limitation. Injectable semaglutide lasts roughly 7 days. Even liraglutide holds for about 13 hours. Danuglipron's clearance rate forced twice-daily dosing in every trial. Pfizer was working on an extended-release once-daily formulation before the program ended.

Danuglipron Benefits

  • Danuglipron benefits center on oral GLP-1 receptor agonism without the limitations of peptide-based oral drugs.
  • Placebo-adjusted weight loss of 5 to 13 percent at 32 weeks in the Phase 2b obesity trial (626 participants)[1]; a third of completers on higher doses lost substantially more.
  • HbA1c reductions up to 1.16 percent versus placebo in type 2 diabetes, with fasting plasma glucose falling 33 mg/dL versus placebo at the highest dose [4].
  • True oral bioavailability without absorption enhancers or fasting windows. Unlike oral semaglutide (Rybelsus), danuglipron can be taken with food and still reach therapeutic plasma levels.
  • Body weight fell 1.9 to 5.4 kg from baseline at 12 weeks in T2D, versus 0.4 kg on placebo [2], even at doses below the obesity trial targets.
  • The clinical data confirmed that small-molecule GLP-1 agonism can produce weight loss in the range of injectable therapies. That proof of concept informed the development of orforglipron, which ultimately reached approval.

Danuglipron: Science vs Community Consensus

Science Only
Scientific Evidence
Moderate
Based on 6 key studies·Research only

Demonstrated meaningful weight loss (−6.9% to −11.7% from baseline at 32 weeks; placebo-adjusted −8% to −13%) and HbA1c reduction (up to −1.16% vs placebo) in Phase 2b trials.

Dosing studied: 10–120 mg BID (T2D Phase 2b); 40–200 mg BID with slow titration (obesity Phase 2b)
Read the evidence (key study, limitations)

Development discontinued April 14, 2025 after a single DILI case in a dose-optimization study; never reached Phase 3 or FDA approval.

Key Study

Obesity Phase 2b RCT (PMID 40539310): 626 participants, 26–32 weeks; placebo-adjusted weight loss −8% to −13% at 32 weeks among completers

Limitations

Only 39.3% of obesity Phase 2b participants completed treatment (38% discontinued due to AEs, 22% other reasons). Up to 73% nausea, 47% vomiting at higher doses. Single DILI case halted entire program. No Phase 3 data. Discontinued drug: no approved dosing protocol exists.

Community Experience
Weak
1.5/5
Based on no meaningful community sample: drug never marketed or compounded

Negligible community use: drug never reached market, no compounded versions available.

Community dosing: N/A: no community protocol exists
Read the reports (what users report 2, common issues 3)

Discussed only as a cautionary tale and comparison point against orforglipron in GLP-1 forums.

What users report (2)
  • Oral convenience cited as theoretical advantage over injectables in forum discussions
  • No injection, no reconstitution, no fasting restriction: referenced positively before discontinuation
Common issues (3)
  • Extreme nausea and vomiting (up to 73%/47%) widely discussed as the defining trial failure
  • DILI signal and full program cancellation ended any community interest
  • Not available via compounding: no research-use pathway for human self-administration
Science-Only Evidence

Danuglipron never reached market or compounding availability. All data is from clinical trials (n=626 obesity, n=~415 T2D across arms). Community protocols do not exist. Science-only by default.

Danuglipron Dosage Guide

Clinical TrialPhase 2b trial: danuglipron (PF-06882961) in adults with type 2 diabetes (Saxena et al., JAMA Netw Open 2023)Source (opens in a new tab)
LevelDoseFrequency
Beginner10 mg2x Daily
Moderate80 mg2x Daily
Aggressive120 mg2x Daily
Note:

Danuglipron is an oral tablet. No vials, no reconstitution, no bacteriostatic water. That's the entire practical appeal and why Pfizer invested in this program.

The twice-daily dosing schedule matters. The half-life is roughly 6 to 8 hours, so missing a dose creates a 12 to 16 hour gap in receptor coverage. If you're reading about this compound for research context, the clinical doses ranged from 2.5 mg BID up to 200 mg BID depending on the trial and arm. The obesity trial targeted 40 to 200 mg BID. The T2D trial tested 2.5, 10, 40, 80, and 120 mg BID.

Slow titration is the only tolerability strategy that showed any benefit. The 4-week titration schedule in Cohort 3 of the obesity trial [1] produced the best efficacy data (32 weeks at target dose) and better completion rates than faster titration arms.

This drug is not available from compounding pharmacies. No FDA-approved reference drug exists, which means 503A and 503B pharmacies cannot legally compound it. It is sold only as a lab reagent for research; those products are explicitly not for human consumption.

Cycling

No scheduled off period.

Development discontinued: no approved dosing protocol exists. Phase 2b studies used continuous twice-daily dosing for 26-32 weeks with dose escalation over the first several weeks. The intended clinical use was continuous long-term treatment, similar to other GLP-1 agonists.

Calculate your Danuglipron dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Danuglipron Protocols by Goal

intermediateClinical Trial26–32 weeks (per Phase 2b design)
Titration: low dose
Wk 1–4
40 mg BID · Twice daily (every ~12 hours) · Oral tablet
Titration: mid dose
Wk 5–12
80–120 mg BID · Twice daily · Oral tablet
Target dose
Wk 13–26 (Cohorts 1&2) or 13–32 (Cohort 3)
40–200 mg BID (arm-dependent; most studied: 80, 120, 160, 200 mg BID) · Twice daily · Oral tablet

Expected: Placebo-adjusted weight loss −5% to −9.5% at 26 weeks; −8% to −13% at 32 weeks in completers (note survivorship bias: majority of participants dropped out before reaching these timepoints)

Monitor: Liver enzymes (ALT/AST) are mandatory given confirmed DILI signal. Monitor at baseline, weeks 4, 8, 12, then monthly. Also track nausea/vomiting severity, weight, heart rate.

How to Inject Danuglipron

  1. 1
    Step 1

    Danuglipron was studied as an oral tablet taken twice daily, approximately 12 hours apart.

  2. 2
    Starting dose in the obesity trial was 40 mg BID

    T2D trials started as low as 2.5 mg BID.

  3. 3
    Take with or without food

    Pharmacokinetic data confirmed similar plasma exposure in fed and fasted states.

  4. 4
    Dose escalation followed a titration schedule

    The best-tolerated approach used 4-week steps: 40 mg BID for 4 weeks, then 80 mg BID for 4 weeks, then to target dose.

  5. 5
    Step 5

    Target doses ranged from 80 to 200 mg BID depending on the trial arm and tolerability.

  6. 6
    Step 6

    No syringe, no reconstitution, no injection technique required. This is a pill.

  7. 7
    Step 7

    Liver function tests (ALT, AST, ALP, total bilirubin) required at baseline, weeks 4, 8, 12, and monthly thereafter. Any reading above 3 times the upper limit of normal requires immediate discontinuation.

  8. 8
    Step 8

    Store tablets at room temperature, 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit).

Danuglipron Stacking Protocols

Works With

Avoid

Semaglutide

Concurrent GLP-1 receptor agonism: additive GI toxicity, increased hypoglycemia risk, no pharmacological benefit. Dual GLP-1 agonist use is contraindicated by mechanism.

Do not combine
Tirzepatide

GLP-1/GIP dual agonist: overlapping GLP-1 mechanism. Additive nausea, vomiting, and hypoglycemia risk. Avoid concurrent use.

Do not combine
Liraglutide

GLP-1 receptor agonist duplication. Additive GI toxicity, nausea, and hypoglycemia risk.

Do not combine
Orforglipron

Same drug class (oral small-molecule GLP-1 agonist). Duplicate mechanism with no benefit; additive GI and potential liver enzyme concerns.

Do not combine

Estimated Cost

Danuglipron Side Effects

The GI side effect profile was severe enough to define the clinical story. Nausea reached 73 percent in one obesity trial arm (140 mg twice daily) versus 15 and 11 percent in the two placebo groups [1]. Vomiting hit 47 percent. Those are not typos.

Across all dose groups in the Phase 2b obesity trial, 38 percent of participants dropped out specifically because of adverse events. Total discontinuation exceeded 60 percent. For comparison, placebo dropout was around 40 percent. That gap makes the tolerability problem clear.

The GI burden stacked: nausea (20 to 48 percent across T2D dose groups), vomiting (18 to 41 percent), diarrhea, dyspepsia, decreased appetite, and abdominal pain were all reported at rates well above placebo [2]. Most of these events clustered during dose escalation. Slower titration schedules (4-week steps versus 1-week steps) appeared to improve tolerability without sacrificing efficacy, but even the slowest titration arms had high dropout.

The most consequential safety signal was drug-induced liver injury. A single participant in a dose-optimization study developed raised liver enzymes consistent with potential DILI. The participant was asymptomatic and recovered after stopping danuglipron. Across the broader safety database of over 1,400 participants, liver enzyme elevation rates fell within the range seen with approved GLP-1 agents. Pfizer still chose to discontinue the entire program after consulting with regulators.

Heart rate increases were observed at Day 28 in Phase 1 data [3]. No serious cardiac events occurred during the trial program, but the observation is consistent with the GLP-1 class effect seen with other drugs in this category.

If you're looking at this compound for any reason, liver function tests are non-negotiable. ALT and AST must be checked at baseline, at weeks 4, 8, and 12, and monthly after that. Any reading above 3 times the upper limit of normal means stop immediately. Symptoms of liver injury (jaundice, right upper quadrant pain, dark urine, unusual fatigue) require emergency evaluation. Do not restart without specialist guidance.

Pregnancy safety data does not exist. GI side effects severe enough to prevent adequate hydration or nutrition are also a reason to stop.

Common Issues & Solutions

Nausea and vomiting are the primary dose-limiting toxicities: up to 73% nausea and 47% vomiting in obesity Phase 2b at higher doses; slower titration (4-week vs 1-week steps) appeared to improve tolerability without sacrificing efficacy

High overall discontinuation rate (~61% in obesity trial) does not reflect tolerance: most dropouts occurred during escalation before reaching target dose; do not interpret high tolerability as a personal failure

Liver enzyme monitoring is mandatory given the DILI signal: baseline LFTs before any use, recheck at weeks 4, 8, and 12, then monthly; stop immediately if ALT or AST exceeds 3× ULN

Short half-life (~6–8 hours) means consistent twice-daily timing is critical: missed doses create 12–16 hour coverage gaps; set alarms and take doses at the same times daily

GI symptoms often peak during dose escalation and may plateau at steady-state dose: if symptoms are intolerable during escalation, hold the current dose for additional weeks rather than escalating further

Ask AI about this page

Ask AI for a second opinion on Danuglipron dosing and side effects

Contraindications

  • Development discontinued: not available for clinical use
  • History of drug-induced liver injury or significant hepatic impairment
  • Personal or family history of medullary thyroid carcinoma (GLP-1 class concern)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Pregnancy or planning to become pregnant (no reproductive safety data)
  • Known hypersensitivity to danuglipron or any excipient
  • Concurrent use with other GLP-1 receptor agonists

Drug Interactions

  • Hepatically metabolized: potential interactions with CYP enzyme inhibitors and inducers (specific CYP isoforms not fully characterized in published data)
  • Insulin and sulfonylureas: increased hypoglycemia risk when combined with GLP-1 agonists
  • Oral medications affected by delayed gastric emptying: GLP-1 agonism slows gastric motility, potentially altering absorption of co-administered drugs
  • Hepatotoxic medications: given the DILI signal, theoretical additive risk with other hepatotoxic agents (acetaminophen at high doses, statins, certain antibiotics)
  • No formal drug interaction studies were published before discontinuation
  • Concurrent GLP-1 receptor agonism: additive GI toxicity, increased hypoglycemia risk, no pharmacological benefit. Dual GLP-1 agonist use is contraindicated by mechanism.
  • GLP-1/GIP dual agonist: overlapping GLP-1 mechanism. Additive nausea, vomiting, and hypoglycemia risk. Avoid concurrent use.
  • GLP-1 receptor agonist duplication. Additive GI toxicity, nausea, and hypoglycemia risk.
  • Same drug class (oral small-molecule GLP-1 agonist). Duplicate mechanism with no benefit; additive GI and potential liver enzyme concerns.
  • Danuglipron carries a confirmed DILI signal. Concurrent hepatotoxic agents theoretically increase liver injury risk. No formal drug interaction data was published before discontinuation.

Product Quality

Recommended Monitoring

TestWhenTarget
Liver function tests (ALT, AST, ALP, total bilirubin)Baseline before any use; weeks 4, 8, 12; monthly at steady-state doseALT/AST <3× ULN required to continue; any elevation above this threshold warrants immediate discontinuation
Fasting blood glucose and HbA1cBaseline; every 8 weeks during treatmentFBG 70–99 mg/dL (euglycemic); HbA1c per individual glycemic targets
Body weightBaseline; every 2 weeks during titration; every 4 weeks at target doseNot listed
Resting heart rateBaseline; monthly60–100 bpm resting; flag sustained increase >10 bpm above individual baseline
Liver function tests (ALT, AST, ALP, total bilirubin)

Confirmed DILI signal from Phase 3 dose-optimization study (single participant with elevated liver enzymes resolving after drug discontinuation). Risk is unquantified without Phase 3 safety data.

Fasting blood glucose and HbA1c

GLP-1 mechanism lowers blood glucose: relevant for anyone with T2D or metabolic syndrome. Hypoglycemia risk is elevated if combined with insulin or sulfonylureas.

Body weight

Primary efficacy endpoint. Rapid weight loss (>1.5 lb/week sustained) may warrant dose assessment; plateaued weight loss at tolerable dose is the expected steady-state.

Resting heart rate

Phase 1 MAD study showed heart rate increases at Day 28: a GLP-1 class effect observed with danuglipron. Relevant for individuals with pre-existing arrhythmia or tachycardia.

Danuglipron Before and After

Weeks 1-4

Dose escalation phase starting from low doses (2.5-10 mg BID). GI side effects most pronounced during this period: nausea, vomiting, and dyspepsia were commonly reported. Modest appetite suppression may begin. Minimal weight change expected.

Weeks 5-12

Escalation toward target dose (80-120 mg BID). In T2D trials, HbA1c fell up to 1.16 points more than placebo at 16 weeks (PMID 37213102). Body weight fell 1.9 to 5.4 kg from baseline at 12 weeks, versus 0.4 kg on placebo (PMID 37311722). GI side effects may persist or worsen with dose increases.

Weeks 13-26

Continued weight loss at target dose. Phase 2b obesity trial showed placebo-adjusted weight loss of -5% to -9.5% at 26 weeks. However, over 50% of participants had discontinued by this point in trials, primarily due to GI adverse events.

Weeks 27-32

Maximum observed efficacy window in Phase 2b. Placebo-adjusted weight loss reached -8% to -13% at 32 weeks in the highest dose groups among those who remained on treatment: though this reflects a survivorship bias given the high dropout rates.

What to Expect

Weeks 1 to 4: Dose escalation begins at 10 to 40 mg twice daily. GI side effects peak during this window. Nausea reached 73 percent in one obesity trial arm (140 mg twice daily), and vomiting reached 47 percent [1]. In a 12-week study, a lower starting dose did not substantially change GI side effects [2]. Appetite suppression may start. Weight change is minimal this early.

Weeks 5 to 12: Escalation toward target dose, typically 80 to 120 mg twice daily. In T2D trials, HbA1c fell up to 1.16 points more than placebo by 16 weeks [4]. Body weight fell 1.9 to 5.4 kg from baseline by 12 weeks, versus 0.4 kg on placebo [2]. GI symptoms may worsen with each dose step. Most trial dropouts occurred during this window.

Weeks 13 to 26: Target dose maintenance. Placebo-adjusted weight loss reached 5 to 9.5 percent at 26 weeks in the obesity trial. Only 39.3 percent of participants made it this far. Liver enzyme monitoring is most important here given cumulative drug exposure.

Weeks 27 to 32: Extended treatment from the longest-running arm (Cohort 3, 4-week titration). Placebo-adjusted weight loss hit 5 to 13 percent at 32 weeks in completers. That number carries serious survivorship bias; the majority of participants had already dropped out.

Detailed Timeline: Science vs Community

Weeks 1–4
Science

Dose escalation from starting dose (10–40 mg BID). GLP-1 receptor occupancy building. Appetite suppression may begin. GI adverse events are most severe during this window.

Community

No community data: drug never marketed.

Weeks 5–12
Science

12-week T2D study: body weight −1.9 to −5.4 kg from baseline vs −0.4 kg on placebo (PMID 37311722). HbA1c begins falling. GI side effects may worsen with each dose step.

Community

No community data.

Weeks 13–26
Science

Obesity Phase 2b (Cohorts 1&2): placebo-adjusted weight loss −5% to −9.5% at 26 weeks. T2D Phase 2b: HbA1c −1.16% vs placebo, fasting glucose −33 mg/dL vs placebo.

Community

No community data. Only 39.3% of obesity trial participants reached this phase.

Weeks 27–32
Science

Obesity Phase 2b Cohort 3 (4-week titration schedule, 32-week treatment): placebo-adjusted weight loss −8% to −13% at 32 weeks in completers. Represents the best-case efficacy from the longest-running arm: significant survivorship bias applies.

Community

No community data.

Pharmacokinetics

Half-Life
7h
Bioavailability
Oral: not formally published; similar exposure in fed vs fasted states indicates food-independent absorption
Tmax
~1-4 hours
Data Confidence
moderate

Source: Saxena et al. Phase 1 MAD study (PMID 34127852); ~6-8 hour terminal half-life necessitating twice-daily dosing

Pharmacokinetics: Active Dose Over Time

t½ = ~6-8 hours

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider Danuglipron

  • Was under development for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities
  • Adults with type 2 diabetes seeking oral GLP-1 options (Phase 2b data only)
  • Researchers studying oral small-molecule GLP-1 receptor agonism
  • Those comparing oral GLP-1 drug candidates (danuglipron vs orforglipron vs oral semaglutide)

Related Peptides

What Changed for Danuglipron

  1. Safety

    Corrected Oct 17, 2026: placebo nausea in the obesity trial was 15 and 11 percent, and the 73 percent peak came at 140 mg twice daily, per NCT04707313.

    Before: Nausea 73 percent in the highest-dose obesity arms versus 12.5 percent on placebo After: Nausea 73 percent in one obesity arm (140 mg twice daily) versus 15 and 11 percent in the two placebo groups

    What this does not mean: Nausea and vomiting still lead the side effects. The 12.5 percent placebo figure came from a separate 12-week diabetes study (PMID 37311722).

    Source: ClinicalTrials.gov NCT04707313, phase 2b dose-ranging study of danuglipron (PF-06882961) in adults with obesity, posted results (published as Buckeridge et al. 2025, PMID 40539310) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]Efficacy and safety of danuglipron in adults with obesity: a Phase 2b study (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Tolerability, safety and pharmacodynamics of danuglipron for type 2 diabetes: a 12-week Phase 2 study (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Efficacy and Safety of Oral Small Molecule GLP-1 Receptor Agonist Danuglipron for Glycemic Control (JAMA Network Open) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Not applicable: oral tablet formulation, store at room temperature
After Reconstitution
Not applicable: oral formulation, no reconstitution needed
Temperature
20-25°C (68-77°F)

Frequently Asked Questions

Pfizer discontinued the twice-daily formulation in 2023 after Phase 2b results showed 8-13% weight loss but high GI discontinuation rates and a confirmed DILI (drug-induced liver injury) signal. A once-daily modified-release version entered Phase 2b in 2024, but Pfizer announced in late 2025 that it would not advance to Phase 3. The program is effectively terminated.

Danuglipron is a small-molecule oral GLP-1 receptor agonist from Pfizer. Unlike semaglutide (a modified peptide), danuglipron is a non-peptide that doesn't require absorption enhancers. It was one of several oral GLP-1 candidates competing with Eli Lilly's orforglipron, which ultimately reached FDA approval first.

GI events (nausea, vomiting, diarrhea) were the most common, with discontinuation rates of 12-22% depending on dose in Phase 2b. The more concerning signal was drug-induced liver injury: ALT and AST elevations exceeding 3x the upper limit of normal triggered mandatory treatment stops. This hepatotoxicity signal was a major factor in the program's discontinuation.

Three factors: (1) the DILI signal required extensive liver monitoring that would limit prescribing; (2) GI tolerability was worse than competitors at comparable efficacy doses; (3) orforglipron (Eli Lilly) reached market first with a cleaner safety profile. Pfizer pivoted its oral GLP-1 efforts to next-generation candidates.

Danuglipron dosing varies by experience level. Beginners typically start at 10 mg 2x daily, moderate users at 80 mg 2x daily, and aggressive protocols use 120 mg 2x daily.